We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Pharming Group is engaged in the development of products for the treatment of unmet medical needs. Pharming Group is engaged in the development of products for the treatment of unmet medical needs.
Pharming Group to participate in September investor conferences PR Newswire LEIDEN, The Netherlands, Aug. 24, 2023 LEIDEN, The Netherlands, Aug. 24, 2023 /PRNewswire/ -- Pharming Group N.V...
Pharming Group to convene Extraordinary General Meeting of Shareholders PR Newswire LEIDEN, The Netherlands, Aug. 14, 2023 LEIDEN, The Netherlands, Aug. 14, 2023 /PRNewswire/ -- Pharming Group...
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan PR Newswire LEIDEN, The Netherlands, Aug. 9, 2023 Single-arm Phase III study...
Pharming Group reports second quarter and first half 2023 financial results PR Newswire LEIDEN, Netherlands, Aug. 3, 2023 RUCONEST® business performed strongly in 2Q 2023; continue to anticipate...
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board PR Newswire LEIDEN, The Netherlands, July 18, 2023 LEIDEN, The Netherlands, July 18, 2023 /PRNewswire/...
Pharming Group to report second quarter and first half 2023 financial results on August 3 PR Newswire LEIDEN, The Netherlands, July 13, 2023 LEIDEN, The Netherlands, July 13, 2023 /PRNewswire/...
Pharming announces sale of priority review voucher PR Newswire LEIDEN, The Netherlands, June 1, 2023 LEIDEN, The Netherlands, June 1, 2023 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DR |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions